This is a single arm, open-label, phase II study to assess pathologic objective response rate
(complete response + partial response) in patients treated with pembrolizumab, paclitaxel and
carboplatin for advanced stage III or IV Ovarian, Fallopian Tube, or Peritoneal Carcinoma
Eligible patients will undergo tissue biopsies to confirm diagnosis, followed by 3 to 4
cycles of neoadjuvant chemotherapy (NACT).
1. No prior treatment for primary advanced (Stage III or IV) high grade epithelial
ovarian, primary peritoneal, or fallopian tube carcinoma such as irradiation,
chemotherapy, hormonal therapy, immunotherapy, investigational therapy, and/or other
concurrent agents or therapies.
2. Patients must undergo diagnostic laparoscopy for disease assessment for tissue
biopsies to confirm diagnosis with planned interval tumor reductive surgery after
completion of 3-4 cycles of treatment. For those not medically fit to undergo
laparoscopy, as determined by the Investigator. (interventional radiology) IR-guided
core biopsies may be used.
3. Patients must be appropriate candidates for planned neoadjuvant chemotherapy with
combination carboplatin and paclitaxel given intravenously (IV) every 3 weeks.
4. Tissue from an archival sample or newly obtained core or excisional biopsy of a tumor
5. Age ≥ 18 years.
6. Life expectancy > 3 months.
7. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
8. Patients must have normal organ and marrow function as defined below:
- Absolute neutrophil count (ANC) ≥1,500 /microliter (mcL).
- Platelets ≥ 100,000 / mcL.
- Hemoglobin ≥ 9 g/dL or ≥ 5.6 mmol/L without transfusion or Erythropoietin
- Serum creatinine ≤ 1.5 X upper limit of normal (ULN) OR
- Measured or calculated a creatinine clearance ≥60 mL/min for subject with
creatinine levels > 1.5 X institutional ULN (GFR can also be used in place
of creatinine or CrCl). Creatinine clearance should be calculated per
- Serum total bilirubin ≤ 1.5 X ULN OR
- Direct bilirubin ≤ ULN for subjects with total bilirubin levels > 1.5 ULN
- Aspartate transaminase (AST/SGOT) and Alanine transaminase (ALT/SGPT) ≤ 2.5
X ULN OR ≤ 5 X ULN for subjects with liver metastases.
- Albumin > 2.5 mg/dL
- International Normalized Ratio (INR) or Prothrombin Time (PT) ≤ 1.5 X ULN
unless subject is receiving anticoagulant therapy as long as PT or PTT is
within therapeutic range of intended use of anticoagulants
- Activated Partial Thromboplastin Time (aPTT) ≤ 1.5 X ULN unless subject is
receiving anticoagulant therapy as long as PT or PTT is within therapeutic
range of intended use of anticoagulants.
9. Negative urine or serum pregnancy ≤ 72 hours (i.e. 3 days) prior to receiving the
first dose of study medication if not surgically sterilized. If the urine test is
positive or cannot be confirmed as negative, a serum pregnancy test will be required.
10. Female subjects of childbearing potential (have not been surgically sterilized or have
not been without menses for > 1 year) should be willing to use 2 methods of birth
control at the same time or be surgically sterile, or abstain from heterosexual
activity for the course of the study and at least 120 days after the last study dose.
11. Ability to understand and the willingness to sign a written informed consent document.
1. Patients who are currently in or have participated in a study of an investigational
agent or used an investigational device within 4 weeks of the first dose of treatment.
2. Histology showing mucinous or low grade epithelial ovarian cancer.
3. Patients who will not be likely to undergo interval tumor reductive surgery either
secondary to performance status or sites of disease. If at the time of surgery, the
patient is deemed to be surgically resectable to no gross residual, the patient will
not be eligible for the study.
4. Patients with known active central nervous system (CNS) metastases and/or
carcinomatous meningitis. Patients with previously treated brain metastases may
participate provided they are stable (without evidence of progression by imaging for
at least four weeks prior to the first dose of Study treatment and any neurologic
symptoms have returned to baseline), have no evidence of new or enlarging brain
metastases, and are not using steroids for at least 28 days prior to Study treatment.
5. Has a known additional malignancy that is progressing or requires active treatment.
Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the
skin, or in situ cervical cancer that has undergone potentially curative therapy.
6. Has received prior therapy with an anti-PD1, anti-PDL1, anti-CD137, anti-cytotoxic
T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other
antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
or anti-PDL2 agent.
7. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
8. Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other
form of immunosuppressive therapy within 7 days prior to the first dose of study
9. Prior monoclonal antibody within 4 weeks prior to study Day 1 or who has not recovered
(i.e. ≤ Grade 1 or at baseline) from adverse events due to agents adverse events
administered more than 4 weeks earlier.
10. Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2
weeks prior to study Day 1 or has not recovered (i.e. ≤ Grade 1 or at baseline) from
adverse events due to previously administered event.
Note: Subjects with ≤ Grade 2 neuropathy are an exception to this criterion and may
qualify for this study. If subject received major surgery, they must have recovered
adequately from the toxicity and/or complications from the intervention prior to
11. Has active autoimmune disease that has required systemic treatment in the past two
years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive
drugs). Replacement therapy (i.e. thyroxine, insulin, or physiologic corticosteroid
replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a
form of systemic treatment.
12. Evidence of interstitial lung disease or active, non-infectious pneumonitis
13. Known psychiatric or substance abuse disorders that would interfere with cooperation
with requirements of the study.
14. Is pregnant or breastfeeding or expecting to conceive within the projected duration of
the study, starting with the pre-screening or screening visit through 120 days after
the last dose of study treatment.
15. Known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
16. Known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA
[qualitative] is detected).
17. Received live vaccine within 30 days prior to the first dose of study treatment. Note:
Seasonal influenza vaccines for injection are generally inactivated flu vaccines and
are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live
attenuated vaccines, and are not allowed.
18. Patient has active bacillus tuberculosis (TB).
19. Patient with known hypersensitivity to pembrolizumab or any of its excipients.
20. Patient receiving concurrent additional biologic therapy.
21. History of allergic reactions attributed to compounds of similar chemical or biologic
composition to carboplatin, paclitaxel not responsive to traditional desensitization
22. Any other serious medical or psychiatric illness/condition likely in the judgment of
the Investigator(s) to interfere or limit compliance with study
23. Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or
child who is an investigational site or sponsor staff directly involved with this
trial, unless prospective institutional review board (IRB) approval (by chair or
designee) is given, allowing exception to this criterion.